Demographics and baseline clinical characteristics of newly diagnosed MM with measurable disease and with oligosecretory, nonsecretory, nonproducer myeloma
| Patients’ characteristics . | Oligosecretory myeloma (N = 61) . | Nonsecretory myeloma (N = 19) . | Nonproducer myeloma (N = 7) . | Measurable disease (N = 735) . | P . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Bortezomib (N = 30) . | Thalidomide (N = 31) . | Bortezomib (N = 6) . | Thalidomide (N = 13) . | Bortezomib (N = 3) . | Thalidomide (N = 4) . | Bortezomib (N = 280) . | Thalidomide (N = 455) . | ||
| Sex, n/N (%) | .575 | ||||||||
| Female | 9/61 (14.75) | 15/61 (24.59) | 1/19 (5.26) | 4/19 (21.05) | 0/7 (0.00) | 1/7 (14.29) | 99/735 (13.47) | 172/735 (23.40) | |
| Male | 21/61 (34.43) | 16/61 (26.23) | 5/19 (26.32) | 9/19 (47.37) | 3/7 (42.86) | 3/7 (42.86) | 181/735 (24.63) | 283/735 (38.50) | |
| Median of age, y | 51 | 57 | 53 | 53 | 57 | 59 | 56 | 59 | .245 |
| Subtype of MM, n/N (%) | .000 | ||||||||
| IgG | 4/61 (6.56) | 5/61 (8.20) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 156/735 (21.22) | 251/735 (34.15) | |
| IgA | 8/61 (13.11) | 9/61 (14.75) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 65/735 (8.84) | 131/735 (17.82) | |
| IgD | 5/61 (8.20) | 7/61 (11.48) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 10/735 (1.36) | 7/735 (0.95) | |
| IgM | 2/61 (3.28) | 1/61 (1.64) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 2/735 (0.27) | 0/735 (0.00) | |
| Light chain type, n/N (%) | |||||||||
| κ | 6/61 (9.84) | 5/61 (8.20) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 16/735 (2.18) | 21/735 (2.86) | |
| λ | 5/61 (8.20) | 4/61 (6.56) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 31/735 (4.22) | 45/735 (6.12) | |
| ISS stage, n/N (%) | .021 | ||||||||
| I | 8/61 (13.11) | 11/61 (18.03) | 2/19 (10.53) | 7/19 (36.84) | 0/7 (0.00) | 1/7 (14.29) | 58/735 (7.89) | 95/735 (12.93) | |
| II | 6/61 (9.84) | 11/61 (18.03) | 2/19 (10.53) | 3/19 (15.79) | 2/7 (28.57) | 2/7 (28.57) | 97/735 (13.20) | 162/735 (22.04) | |
| III | 16/61 (26.23) | 9/61 (14.75) | 2/19 (10.53) | 3/19 (15.79) | 1/7 (14.29) | 1/7 (14.29) | 125/735 (17.01) | 198/735 (26.94) | |
| Durie-Salmon stage, n/N (%) | .064 | ||||||||
| I | 2/61 (3.28) | 5/61 (8.20) | 0/19 (0.00) | 3/19 (15.79) | 0/7 (0.00) | 0/7 (0.00) | 6/735 (0.82) | 32/735 (4.35) | |
| II | 2/61 (3.28) | 4/61 (6.56) | 1/19 (5.26) | 1/19 (5.26) | 1/7 (14.29) | 0/7 (0.00) | 19/735 (2.59) | 51/735 (6.94) | |
| III | 26/61 (42.62) | 22/61 (36.07) | 4/19 (21.05) | 10/19 (52.63) | 3/7 (42.86) | 3/7 (42.86) | 255/735 (34.69) | 372/735 (50.61) | |
| Median albumin, g/L | 43.90 | 48.10 | 41.5 | 38.9 | 41.4 | 31.3 | 34.00 | 33.8 | .000 |
| Renal dysfunction, serum Cr ≥2.0 mg/dL, n/N (%) | 15/61 (24.59) | 6/61 (9.84) | 1/19 (5.26) | 2/19 (10.53) | 1/7 (14.29) | 0/7 (0.00) | 61/735 (8.30) | 73/735 (9.93) | .004 |
| Median hemoglobin, g/L | 100 | 97 | 105 | 80 | 87 | 92 | 91 | 86 | .002 |
| Median platelet count, ×109/L | 193 | 176 | 144 | 130 | 196 | 144 | 175 | 158 | .082 |
| Median LDH, U/L | 235 | 257 | 349 | 179 | 228 | 367 | 174 | 188 | .000 |
| Median calcium, mmol/L | 2.32 | 2.29 | 2.37 | 2.30 | 2.28 | 1.83 | 2.38 | 2.27 | .322 |
| Plasma cells in bone marrow, % | 25.5 | 27.5 | 38.5 | 27.0 | 47.5 | 29.5 | 33.5 | 37.0 | .067 |
| Extramedullary disease, % | 10 | 3 | 2 | 1 | 1 | 0 | 72 | 30 | .072 |
| Patients’ characteristics . | Oligosecretory myeloma (N = 61) . | Nonsecretory myeloma (N = 19) . | Nonproducer myeloma (N = 7) . | Measurable disease (N = 735) . | P . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Bortezomib (N = 30) . | Thalidomide (N = 31) . | Bortezomib (N = 6) . | Thalidomide (N = 13) . | Bortezomib (N = 3) . | Thalidomide (N = 4) . | Bortezomib (N = 280) . | Thalidomide (N = 455) . | ||
| Sex, n/N (%) | .575 | ||||||||
| Female | 9/61 (14.75) | 15/61 (24.59) | 1/19 (5.26) | 4/19 (21.05) | 0/7 (0.00) | 1/7 (14.29) | 99/735 (13.47) | 172/735 (23.40) | |
| Male | 21/61 (34.43) | 16/61 (26.23) | 5/19 (26.32) | 9/19 (47.37) | 3/7 (42.86) | 3/7 (42.86) | 181/735 (24.63) | 283/735 (38.50) | |
| Median of age, y | 51 | 57 | 53 | 53 | 57 | 59 | 56 | 59 | .245 |
| Subtype of MM, n/N (%) | .000 | ||||||||
| IgG | 4/61 (6.56) | 5/61 (8.20) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 156/735 (21.22) | 251/735 (34.15) | |
| IgA | 8/61 (13.11) | 9/61 (14.75) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 65/735 (8.84) | 131/735 (17.82) | |
| IgD | 5/61 (8.20) | 7/61 (11.48) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 10/735 (1.36) | 7/735 (0.95) | |
| IgM | 2/61 (3.28) | 1/61 (1.64) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 2/735 (0.27) | 0/735 (0.00) | |
| Light chain type, n/N (%) | |||||||||
| κ | 6/61 (9.84) | 5/61 (8.20) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 16/735 (2.18) | 21/735 (2.86) | |
| λ | 5/61 (8.20) | 4/61 (6.56) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 31/735 (4.22) | 45/735 (6.12) | |
| ISS stage, n/N (%) | .021 | ||||||||
| I | 8/61 (13.11) | 11/61 (18.03) | 2/19 (10.53) | 7/19 (36.84) | 0/7 (0.00) | 1/7 (14.29) | 58/735 (7.89) | 95/735 (12.93) | |
| II | 6/61 (9.84) | 11/61 (18.03) | 2/19 (10.53) | 3/19 (15.79) | 2/7 (28.57) | 2/7 (28.57) | 97/735 (13.20) | 162/735 (22.04) | |
| III | 16/61 (26.23) | 9/61 (14.75) | 2/19 (10.53) | 3/19 (15.79) | 1/7 (14.29) | 1/7 (14.29) | 125/735 (17.01) | 198/735 (26.94) | |
| Durie-Salmon stage, n/N (%) | .064 | ||||||||
| I | 2/61 (3.28) | 5/61 (8.20) | 0/19 (0.00) | 3/19 (15.79) | 0/7 (0.00) | 0/7 (0.00) | 6/735 (0.82) | 32/735 (4.35) | |
| II | 2/61 (3.28) | 4/61 (6.56) | 1/19 (5.26) | 1/19 (5.26) | 1/7 (14.29) | 0/7 (0.00) | 19/735 (2.59) | 51/735 (6.94) | |
| III | 26/61 (42.62) | 22/61 (36.07) | 4/19 (21.05) | 10/19 (52.63) | 3/7 (42.86) | 3/7 (42.86) | 255/735 (34.69) | 372/735 (50.61) | |
| Median albumin, g/L | 43.90 | 48.10 | 41.5 | 38.9 | 41.4 | 31.3 | 34.00 | 33.8 | .000 |
| Renal dysfunction, serum Cr ≥2.0 mg/dL, n/N (%) | 15/61 (24.59) | 6/61 (9.84) | 1/19 (5.26) | 2/19 (10.53) | 1/7 (14.29) | 0/7 (0.00) | 61/735 (8.30) | 73/735 (9.93) | .004 |
| Median hemoglobin, g/L | 100 | 97 | 105 | 80 | 87 | 92 | 91 | 86 | .002 |
| Median platelet count, ×109/L | 193 | 176 | 144 | 130 | 196 | 144 | 175 | 158 | .082 |
| Median LDH, U/L | 235 | 257 | 349 | 179 | 228 | 367 | 174 | 188 | .000 |
| Median calcium, mmol/L | 2.32 | 2.29 | 2.37 | 2.30 | 2.28 | 1.83 | 2.38 | 2.27 | .322 |
| Plasma cells in bone marrow, % | 25.5 | 27.5 | 38.5 | 27.0 | 47.5 | 29.5 | 33.5 | 37.0 | .067 |
| Extramedullary disease, % | 10 | 3 | 2 | 1 | 1 | 0 | 72 | 30 | .072 |